[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Universitaire de Nice\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":512},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,159,0,25,[9,41,66,85,106,122,140,156,174,197,214,234,253,273,290,305,326,347,370,392,410,431,452,473,492],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100633817","assessment-of-intra-abdominal-pressure-during-the-perioperative-period-of-hernia-repair-100633817",false,"NCT07531615","Assessment of Intra-abdominal Pressure During the Perioperative Period of Hernia Repair","PRESSEVENT","Inclusion Criteria:\n\n* Midline incisional hernias with a hernia defect width between 4 and 10 cm in the transverse axis, corresponding to W2 according to the EHS classification\n* M2, M3, and M4 locations according to the EHS classification (i.e., hernia defects located from 3 cm below the xiphoid process to 3 cm above the upper border of the pubic symphysis)\n* Patients scheduled for elective open midline incisional hernia repair with retromuscular mesh placement\n* Provision of written informed consent\n* Affiliation with a national health insurance system\n\nExclusion Criteria:\n\n* Other types of incisional hernia\n* Minimally invasive surgery (laparoscopic or robotic approach)\n* Patients under legal protection (guardianship or curatorship), or patients unable to participate in a clinical study in accordance with Article L.1121-16 of the French Public Health Code\n* Pregnant or breastfeeding women of childbearing age","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","Thousands of patients worldwide undergo abdominal surgery every day; 2-11% of laparotomies will progress to an incisional hernia, particularly midline laparotomies, which are associated with higher hernia rates, reaching up to 70% in obese patients (1,2). Long-term recurrence after incisional hernia repair is close to 30% after primary repair and may increase to 70% in cases of iterative (redo) surgery (3).\n\nThe main risk factors for incisional hernia formation or recurrence include surgical site infection, surgical technique, respiratory insufficiency (COPD), as well as overweight and obesity, the prevalence of which is rapidly increasing.\n\nMidline incisional hernias are the most frequent and represent a significant public health issue.\n\nIn abdominal wall surgery, some teams perform so-called tension-free repairs, whereas others favor repairs under tension. The tension-free concept may be associated with a lower recurrence rate. However, this intuitive concept has never been mechanically defined, using perioperative pressure measurements or surface tension assessment. Few studies have investigated abdominal pressure and muscle tension measurements in relation to abdominal wall surgery.\n\nThe aim of this study is to evaluate a protocol for measuring abdominal pressures during open repair of midline incisional hernia.",[27],"Hernia Incisional","RECRUITING","2026-07-01",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":21},"2026-07-30",{"date":36,"type":21},"2028-08-01",{"name":38,"class":39},"Centre Hospitalier Universitaire de Nice","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100645049","sexual-and-urinary-dysfunctions-in-generalized-myasthenia-100645049","NCT07677852","Sexual and Urinary Dysfunctions in Generalized Myasthenia","Sexual and Urinary Dysfunctions in Generalized Myasthenia: Impact on Quality of Life - the MYAOUS Study","MYAOUS","Inclusion Criteria:\n\n1. Minimum age of 18 years at the time the informed consent form is obtained.\n2. Confirmed diagnosis of generalized autoimmune myasthenia gravis, including at least two of the following:\n\n   1. Typical clinical features assessed by a physician specializing in myasthenia gravis\n   2. A decrease of ≥ 10% during repeated nerve stimulation (3-5 Hz) or increased irregularity on a single-fiber electromyogram\n   3. A positive edrophonium test or response to anticholinesterase agents\n   4. Serum anti-AChR or anti-MuSK antibodies.\n3. Enrolled in or covered by a social security program in accordance with current regulations governing research involving human subjects.\n\nExclusion Criteria:\n\n1. Pregnant (at the time of enrollment)\n2. Postpartum \\\u003C 6 months\n3. Severe cognitive impairment or under legal guardianship, making it impossible to understand or complete self-administered questionnaires.",{"count":50,"type":21},150,"OBSERVATIONAL","Myasthenia gravis is an autoimmune disease caused by specific autoantibodies that disrupt the function of the neuromuscular junction. It manifests as excessive fatigue of the skeletal muscles during physical exertion and affects 15,000 people in France. Initial symptoms are most often ocular (ptosis, diplopia) but can later spread throughout the body, potentially leading in some cases to respiratory failure and\u002For swallowing difficulties (myasthenic crisis) or even death. This condition is currently being managed more effectively through treatment, and the invisible symptoms (sexual dysfunction, sphincter dysfunction, psychological impact, etc.) may ultimately be more debilitating than the initial symptoms, which are often controlled by maintenance and\u002For symptomatic treatments. The impact of myasthenia gravis on intimate life remains a taboo subject and is poorly understood by both the medical community and patients. In the literature, only a single article from 2021 addresses sexual dysfunction in patients with myasthenia gravis. Urinary disorders in myasthenia gravis are frequently reported but have also been little studied.\n\nA national survey, conducted using an online questionnaire distributed by patient associations, shed light on the disease's impact on patients' intimate lives. In this study of 190 patients, 46 of them responded to the question about sexual function, and one in two patients reported sexual complaints; in 46% of cases, this disorder significantly impacted the patients' daily lives. In particular, a decrease in the frequency of sexual intercourse with a partner was noted in 55% of cases, as well as a decrease in sexual desire in 51% of cases.\n\nSexual dysfunction is very common and underreported in many chronic neurological diseases. The Sexual Complaints Screener (SCS W\u002FM) questionnaires for women and men in English have very recently been validated in French (Questionnaires de Plaintes Sexuelles, QPS F\u002FH).\n\nIt now have a 10-item self-administered questionnaire that assesses the full range of sexual disorders and their impact.\n\nIn conclusion, while the visible symptoms of myasthenia gravis are widely recognized, the invisible symptoms-such as genitourinary and sphincter disorders-remain largely unrecognized and underdiagnosed. It is therefore essential to conduct systematic screening in order to best guide our patients and thereby improve their quality of life.",[54],"Myasthenia Gravis (MG)",[56,57],"genitourinary and sphincter disorders","Myasthenia gravis","NOT_YET_RECRUITING","2026-06-26",{"date":29,"type":32},{"date":34,"type":21},{"date":63,"type":21},"2030-07-30",{"name":38,"class":39},2,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100532738","study-of-the-location-of-motor-cortical-stimulation-electrodes-in-chronic-neuropathic-refractory-patients-100532738","NCT06216717","Study of the Location of Motor Cortical Stimulation Electrodes in Chronic Neuropathic Refractory Patients","Inclusion Criteria\n\n* adults\n* patient implanted with a motor cortical stimulation system for chronic neuropathic refractory pain,\n* patient with available postoperative scanner\n\nExclusion Criteria: None",{"count":73,"type":21},100,"Cortical stimulation has been used since 1991 to treat neuropathic pain. However, the underlying mechanisms are still incompletely understood and under-studied. In this protocol, the investigators aim to study the myeloarchitectonic and functional characteristics of areas activated by cortical epidural electrodes and to determine their relation to therapy response in chronic neuropathic refractory pain patients.",[76],"Neuropathic Pain","2026-06-25",{"date":79,"type":32},"2026-06-29",{"date":81,"type":32},"2023-11-13",{"date":83,"type":21},"2027-06-25",{"name":38,"class":39},{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":40},"100512709","characteristics-of-hoffa-adipose-tissue-and-intramuscular-adipose-tissue-in-the-quadriceps-muscle-100512709","NCT05955976","Characteristics of Hoffa Adipose Tissue and Intramuscular Adipose Tissue in the Quadriceps Muscle","Study to Compare the Characteristics of Hoffa Adipose Tissue and Intramuscular Adipose Tissue in the Quadriceps Muscle","ADIPENIGME","Inclusion Criteria:\n\n* Adult patient, aged between 40 and 85 years\n* Patient having a confirmed diagnosis of knee ostheoarthritis\n* Patient undergoing a surgery for a total knee prosthesis for knee ostheoarthritis\n\nExclusion Criteria:\n\n\\-","40 Years","85 Years",{"count":96,"type":21},20,"Over the last few years, it has been suggested that Knee Ostheoarthritis (KOA) incidence and progression could potentially be related to skeletal muscle characteristics. In particular, weakness of the quadriceps muscle would be a key determinant of KOA. However the mechanisms underpinning the influence of skeletal muscle in the pathophysiology of ostheoarthritis (OA) are poorly understood.\n\nCrosstalk between skeletal muscle and structures around and in the joint is of interest. In physical deconditioning and aging, it has been reported that skeletal muscle can be replaced by adipose tissue. Several factors involved in the development of OA but also of adipose tissue may be involved in these muscular changes. Of interest, in patients with KOA, quadriceps weakness is an ubiquitous clinical finding. Infiltration of adipose tissue in skeletal muscle has been shown to affect muscle strength and mobility and be linked to cartilage volume loss and the occurrence\u002Fprogression of KOA.\n\nThe main objective of this study is to compare the characteristics of the Hoffa tissus and the intamuscular fat (IMF) tissus in the quadriceps muscle in patients with gonarthrosis requiring total knee prosthesis.\n\nThis is a single-centre study based on a collection of surgical waste and is categorized as Research Not Involving Human subjects.",[99],"Osteo Arthritis Knee",{"date":79,"type":32},{"date":102,"type":32},"2023-07-20",{"date":104,"type":21},"2027-06-20",{"name":38,"class":39},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":121,"locationsCount":40},"100507393","prediction-of-the-spontaneous-breathing-test-success-using-biosignal-and-biomarker-in-critical-care-unit-by-a-machine-learning-approach-100507393","NCT05886803","Prediction of the Spontaneous Breathing Test Success Using Biosignal and Biomarker in Critical Care Unit by a Machine Learning Approach","Inclusion Criteria:\n\n* Computerized health report (CHR)\n* Spontaneous breathing test should have been performed\n\nExclusion Criteria:\n\n* Spontaneous breathing test has not been performed,\n* Biosignal (cardiac, respiratory) are not registered in the CHR\n* Patient died before the spontaneous breathing test\n* Opposition to the study has been expressed.",{"count":113,"type":21},500,"Context:\n\nSeveral authors have been interested in applying Artificial Intelligence (AI) to medicine, using various Machine Learning (ML) techniques: managing septic shock, predicting renal failure... \\[1, 2\\] AI has an important place in decision support for clinicians \\[3\\]. The weaning period is a really important time in the management of a patient on mechanical ventilation and can take up to half of the time spent in intensive care unit. The first weaning attempt is unsuccessful in 20% of patients However, mortality can be as high as 38% in patients with the most difficult weaning \\[4\\]. Only a few studies have looked at the application of machine learning in this area, and only one has looked at the use of biosignals (cardiac rate, ECG, ventilatory parameters…) \\[5-7\\]. To improve morbidity, mortality and reduce length of stay, it is essential to be able to predict the success of the spontaneous breathing test and extubation.\n\nInvestigators propose to develop a predictive algorithm for the success of a ventilatory weaning test based on biosignal records and others features.\n\nMethods:\n\nIt is a critical care, oligo-centric and retrospective study the investigators included biosignal variables extracted from the electronic medical record, such as respiratory (RR, minute volume...), cardiac (systolic pressure, heart rate...), ventilator parameters and other discrete variables (age, comorbidity...). Most biosignal variables are minute-by-minute records. Recording starts 48 hours before the test and stops at the start of the weaning test. The investigators extracted features from these records, combined them with other biomarkers, and applied several machine learning algorithms: Logistic Regression, Random Forest Classifier, Support Vector Classifier (SVC), XGBoost, and Light Gradient Boosting Method (LGBM)…",[116],"Weaning From Mechanical Ventilation in Care Unit",{"date":79,"type":32},{"date":119,"type":32},"2023-01-01",{"date":83,"type":21},{"name":38,"class":39},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":139,"locationsCount":40},"100486142","study-of-the-metabolism-in-the-lymphatic-niche-of-cll-100486142","NCT05610228","Study of the Metabolism in the Lymphatic Niche of CLL","Study of the Metabolic Reprogramming of CLL Cells in Ex-vivo Models of the Lymphatic Niche","Inclusion Criteria:\n\n* Patients for whom the diagnosis of CLL has been established cytologically and phenotypically (Matutes score)\n* Patients over 18 years old\n* Patients who have signed the non-objection form\n* Untreated patients\n\nExclusion Criteria:\n\n* Patient with a solid cancer that is progressive or in remission for less than 3 years\n* HIV positive patients\n* Patients with chronic active hepatitis B or C\n* History of allogeneic transplant","90 Years",{"count":131,"type":21},30,"Chronic lymphoid leukemia (CLL) is the most common adult leukemia that is characterized by a malignant monoclonal accumulation of tumoral and quiescent B cells in the peripheral blood. In advanced stages of the disease (Binet stage C), this population invades the bone marrow (BM) and proliferate into the lymphoid organs that results in widespread adenopathy. Richter's transformation is a most aggressive serious complication of CLL (transformation of the disease into an aggressive lymphoma) detected based on TEP\u002FCT (Positron Emission Tomography\u002F computerized tomography) that shows highly derived glucose consumption by cancer cells. Clinical data from CLL patients with disease acutisation showed hypermetabolic lymphadenopathy with high standardized uptake value (SUV) whereas there is low grade tracer uptake into BM. We supposed that the tumor microenvironment of the lymphatic niche promotes the proliferation and glycolytic activity of CLL cells which become particularly resistant to treatment. The development of an ex-vivo tumor model that reproduces the microenvironment of the lymph node niche appears essential to identify and validate new therapeutic targets because despite the therapeutic arsenal available some patients still relapse or are refractory to treatment. Our objectives are to i \u002F Characterize this niche of resistance by the development of an ex-vivo tumor model and ii \u002F Evaluate in-vitro the effectiveness of the association of current treatments (RFC, Ibrutinib or Venetoclax) with anti-metabolic therapies (inhibitors of glycolysis) Our lab is developing an ex-vivo models of the lymphatic niche in CLL based on co-cultures of leukemic cells from patients stimulated with CpG ODN and IL2 with primary human lymphatic fibroblasts (HLF) (EC 12PP15). This co-culture has never been described in the literature and allows us to study the lymphatic niche of CLL patients. Lymph node (LN) exploration in CLL requires invasive access and does not bring any additional information in initial diagnosis. Then, we validated our co-culture model using complementary approaches: increased viability, proliferation, and resistance to Ibrutinib, associated with increased production of anti-apoptotic proteins such as MCL1 and BCL2 after 48 hours of co-culture. Secondly, we studied the metabolism in this resistance niche. We find an increased production of lactate and an acute consumption of glucose, associated with a strong metabolic activation detected by SEAHORSE and by the production of glycolysis enzymes such as hexokinase 2. Our study constitutes an original project because it characterized the energy metabolism of the CLL lymphatic niche by developing an original ex-vivo model and enhanced our understanding of the contribution of the specific microenvironment in the dissociation of metabolic activity using SUV max in BM and lymphatic niche. Anti-metabolic therapies are efficient on co-culture CLL cells and could be an alternative for refractory or relapsed patients under current treatment.",[134],"CLL",{"date":79,"type":32},{"date":137,"type":32},"2018-11-07",{"date":83,"type":21},{"name":38,"class":39},{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":155,"locationsCount":40},"100484867","thromboxane-a2-and-osteoarthritis-100484867","NCT05593640","Thromboxane A2 and Osteoarthritis","Throboxane Effect on Chondrocytes; Role in Osteoarthritis","Inclusion Criteria:\n\n* presence of knee osteoarthritis with effusion, , no inflammatory disease\n\nExclusion Criteria:\n\n* anticoagulant treatment\n* inflammatory disease",{"count":96,"type":21},"TXA2 inhibits the expression of the primary marker of thermogenesis (UCP1) while prostacyclin (PGI2), another metabolite derived from arachidonic acid, enhances its expression. Given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane A2 controls chondrocyte formation and function and thus cartilage homeostasis. The study objectives are: i) to analyse the role of TXA2 on chondrocyte differentiation in vitro, ii) to determine the association between circulating and tissue TXA2 levels in a rat model of osteoarthritis, and iii) to correlate circulating and synovial fluid levels of TXA2 with the development of osteoarthritis in a small human cohort. The proposed research aims to better understand the mechanisms underlying the role of lipid metabolites in chondrocyte formation and function, paving the way for the development of nutritional and pharmacological therapies to combat OA and associated metabolic disorders.",[150],"Osteoarthritis",{"date":79,"type":32},{"date":153,"type":32},"2022-09-01",{"date":83,"type":21},{"name":38,"class":39},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":173,"locationsCount":40},"100443617","combined-analysis-of-inflammatory-biomarkers-for-cns-autoimmune-diseases-diagnostic-100443617","NCT05056740","Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic","Evaluation of a Combined Analysis of Serum and Cerebrospinal Fluid Inflammatory Biomarkers to Help in Etiological Diagnosis of Central Nervous System Autoimmune Diseases","CyBIRD","Inclusion Criteria:\n\n* Patients referred to our center for the diagnostic work-up of White Matter Lesions\n* Patients that need a routine blood analysis\n* Patients that need a routine CSF analysis\n* Non opposition to research consent\n\nExclusion Criteria:\n\n* Patients with a contraindication to perform spinal tap (increase bleeding risk medicine or disease)\n* Patients with a contraindication to MRI (metal prosthesis…)",{"count":165,"type":21},300,"Project rationale:\n\nSince 2017, multiple sclerosis diagnosis should match the new McDonald criteria in which a \"no better explanation than MS\" should be fulfilled. However, many patients present with red flags that lead to a complex diagnostic work-up. There are no available biomarkers that permit to confirm or roll out MS diagnosis in such cases. Therefore, we lack biological markers that can help in the diagnosis of patients presenting with suspected MS.\n\nMany studies have found that serum and cerebrospinal fluid (CSF) cytokines could help to differentiate MS from other diseases such as neuromyelitis optica spectrum disorders (i.e., IL-6) or neurosarcoidosis (i.e., sIL-2R). Serum and CSF kappa free light chains have also shown good diagnosis performance in MS. In daily practice, our MS tertiary center already perform the analysis of CSF concentrations of IL-1β, sIL-2R, IL-6, IL-10, and serum and CSF kappa and lambda free light chains to roll out other central nervous system (CNS) autoimmune diseases in patients presenting with white matter hyperintensities (WMH).\n\nObjective:\n\nTo correlate CSF IL-1β, sIL-2R, IL-6, IL-10, serum and CSF kappa and lambda free light chains with the final diagnosis in patients presenting to our MS tertiary center with suspected MS to identify a specific inflammatory biomarker profil involved in MS and other CNS autoimmune diseases.\n\nThe methodology:\n\nThis is an observational study. All patients ongoing a routine diagnostic work-up for suspected MS from june 2020 to june 2022 in our MS tertiary center will be analyzed. Cerebrospinal fluid IL-1β, sIL-2R, IL-6, IL-10, serum and CSF kappa and lambda free light chains will be correlated with the final diagnosis to ultimately find MS associated biomarkers.",[168],"Central Nervous System Diseases",{"date":59,"type":32},{"date":171,"type":32},"2020-06-01",{"date":83,"type":21},{"name":38,"class":39},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":17,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":196,"locationsCount":40},"100433358","impact-of-auditory-stimulation-in-eating-pleasure-edere-2021-100433358","NCT04923087","Impact of Auditory Stimulation in Eating Pleasure (EDERE 2021)","Impact of Auditory Stimulation in Eating Pleasure : Multicentric Study With Biscuits With Crunchy Texture vs Soft Texture in 100 Seniors Affected or at Risk of Presbyacusis","EDERE 2021","Inclusion Criteria:\n\nSubjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents.\n\nExclusion Criteria:\n\nrisk of false route when eating cookies, allergy to an ingredient in cookies",true,"65 Years",{"count":73,"type":21},"Background. Decreased taste and smell contribute to loss of appetite (anorexia), and the resulting protein-energy malnutrition increases the frailty of the elderly. The risk of falls, disability, infections and depression often requires them to be institutionalized. Elderly, undernourished and toothless patients often complain about the monotony of a soft, mixed-texture diet. In a previous study, some participants highlighted the pleasure of crunching cookies that have a solid texture that can be eaten in any dental condition. However, the age-related decrease in hearing (presbyacusis) is frequent and progressive from the age of 60. The hypothesis of this work is that older patients may perceive a crunchy food crunching in their mouth, despite presbycusis. If the hypothesis is verified, this would make geriatric caregivers aware of the possibility of diversifying the texture of food, in order to stimulate the pleasure of eating and increase the dietary intake in this population of patients who are often undernourished, dysphagic, edentulous and hearing impaired. The originality of this study is to share the expertise of geriatricians and specialists in mastication\u002Fswallowing (dental surgeon, speech-language pathologist), hearing (ENT doctor, hearing care professional) and nutrition (dietician).\n\nType of study. Type of study MR-004 \"Research not involving the human person\". Protocol. Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements: a soft filled cookie (Nutra Cake™, Délical, France) and a crunchy cookie of the Breton type (Protibis™, Solidages, France). Blind study impossible: each subject will eat a cookie then the other in a random order and will be his own control. The tests will be performed without the possible hearing aids, but with or without the dentures according to the patient's preference. Indeed, some patients have dental prostheses that are no longer suitable for chewing, and that they wear only for aesthetics. Objective. Validate the evaluation criteria \"Do you hear the biscuit crunch?\" and \"Is it a pleasure?\" If so, encourage diversification with crunchy foods with a suitable texture, as well as dental and prosthetic rehabilitation of dependent elderly people.",[187,188,189,190,191],"Frailty","Malnutrition","Anorexia","Presbycusis","Edentulism Nos",{"date":79,"type":32},{"date":194,"type":32},"2021-06-01",{"date":83,"type":21},{"name":38,"class":39},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":213,"locationsCount":40},"100397996","aicr--artificial-intelligence-in-cardiac-arrest-100397996","NCT04462380","AiCR : Artificial Intelligence in Cardiac aRrest","AiCR : Artificial Intelligence in Cardiac aRrest Application of an Algorithm in the Prognosis of Recovered Cardiorespiratory Arrests","AiCR","Inclusion Criteria:\n\n* OCA recovered from: hypoxic, ischemic, pulmonary embolism, tamponade, rhythm or conduction disorder, shockable or not, intra or extra-hospital.\n* CR computerized, typed in PDF format\n\nExclusion Criteria:\n\n\\-",{"count":113,"type":21},"The overall incidence of cardiorespiratory arrest in Europe is estimated at 350,000 to 700,000 cases per year. Survival rate is estimated at 10.7% for all rhythm disorders combined.\n\nSeveral examples of AI application in the medical field exist. Ting et al have developed a computer tool capable of diagnosing the presence of diabetic retinopathy with excellent power. In resuscitation, Celi et al proposed a tool capable of predicting the need for crystalloid vascular filling during a systemic inflammatory state. In Nature in 2018, Komorowski demonstrated the efficacy of AI in the hemodynamic management of sepsis. In a study of the renal response to fluid challenge, Zhang et al. demonstrate the effectiveness of the learning machine.\n\nObjectives: Determination of an algorithm capable of predicting the mortality of patients admitted to intensive care units (ICU) for ACR from hospitalization reports (CRH). Also use of the algorithm to predict the risk of recurrence of the arrest, the duration of mechanical ventilation, the appearance of sepsis, the development of organ failure, prediction of the CPC (Cerebral Performance Category), time to obtain catecholamine withdrawal, the appearance of acute renal failure with or without the need for extra-renal purification (EER) and duration under EER, the average length of stay.\n\nThis project is part of a larger, nationwide project with greater power, and includes all the data generated during hospitalization in intensive care.\n\nMethod: an estimated total number of patients included in this study to be between 300 and 500. The population will come from the intensive care units of Nice, Antibes, Cannes, Grasse.\n\nInclusion will be retrospective, on CRH, CR of CT imaging (cerebral and thoraco-abdomino-pelvic), MRI, EEG, and daily follow-up words, from 2014 to the end of 2020.\n\nAfter anonymisation, application of semantisation using natural language processing (NLP) methods. The data to be extracted are entered in a document written by intensive care physicians. These data will then be stored in a database. In order to meet the main objective, we will develop a computer algorithm capable of predicting mortality in the study population. This algorithm, based on a large database, can be designed using machine learning or even deep learning techniques depending on the amount of data to be processed.",[208],"Cardio Respiratory Arrest",{"date":79,"type":32},{"date":211,"type":32},"2020-02-01",{"date":83,"type":21},{"name":38,"class":39},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":221,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":233,"locationsCount":40},"100392456","inflatable-penile-prostheses--which-patients-can-correctly-use-the-scrotal-pump--100392456","NCT04390230","Inflatable Penile Prostheses : Which Patients Can Correctly Use the Scrotal Pump ?","Inflatable Penile Prostheses : Predicting Factors of Pump Misuse and Unsatisfaction","All cases included were discussed and approved by a multidisciplinary team. Patients who underwent prosthesis replacement or second implantation were not included. We excluded patients who refused or were not able to answer our questionnaire, patients who provided unreliable answers, and patients that experimented a secondary malfunction of their IP.","MALE",{"count":223,"type":21},120,"Sexual health and satisfaction are well know as critical critera to assess quality of life, at any age. Among the multiple aspects of sexual health, erectile dysfunction (ED) is not anymore a fate, mainly thanks to the advent of phosphodiesterase type 5 (PDE5) inhibitors in 1998. Nevertheless, a significant part of patients are intolerant or does not respond to PDE5 inhibitors and thus are looking for other treatment options.\n\nSince the first implantation of foreign material intracarvernosally in 1966 by Beheri, multiple modifications and enhancements were achieved in order to produce devices more reliable with a more natural appearance. First introduced in 1973 by Scott et al., inflatable prosthesis provides now high general satisfaction rates (69-94%), better than in malleable prostheses, except for few authors.\n\nIn addition to changes in materials and construction, the two main manufacturers of IPP, Boston scientific AMS (Marlborough, MA, USA) and Coloplast (Minneapolis, MN, USA), modernized the pump mechanism of their devices. Since the introduction of AMS IPP, three main pump formats have been used : the standard pump has been replaced in 2004 by the \" Tactile \" pump and then the \" Momentary Squeeze \" (MS) pump in 2006, smaller and easier to deflate by not requiring the patient to hold the deflation button throughout deflation. Coloplast also replaced in 2008 their \" Genesis \" pump by a \" One Touch Release \" (OTR) pump, and finally in 2014 by the current \" Touch \" pump, smaller, and presenting a biconcave deflation button, easier to find.\n\nDespite all technological advances, appropriate pre-operative counselling and careful post-operative teachning, a significant part of patients has still difficulties to handle the pump and thus, does not use their IPP, regardless of any material malfunction. That situation obviously leads to patient's dissatisfaction and highlights the operating risks of a useless surgical procedure.\n\nThe purposes of this study were:to identify the risks factors, modifiable and non-modifiable, for patients' difficulty to inflate and\u002For deflate their device after IPP implantation, then to show a correlation between easy handling and post-operative satisfaction. And last but not least, to show an association between pre-operative pump pattern viewing and handling and post-operative easy handling. That information could help the physicians to improve the pre-operative selection of patients and to adapt the peri-operative care in order to improve patients satisfaction.",[226,227,228],"Surgery","Satisfaction","Penile Prosthesis; Complications",{"date":79,"type":32},{"date":231,"type":32},"2014-01-24",{"date":83,"type":21},{"name":38,"class":39},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":129,"enrollmentInfo":242,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":40},"100388919","assessment-of-chilbains-occuring-during-covid-19-infection-100388919","NCT04344119","Assessment of Chilbains Occuring During Covid-19 Infection","Assessment of Skin Manifestations Occuring During Covid-19 Infection With a Special Focus on Chilbains","ChilblainCOVID","Inclusion Criteria:\n\n* All patients with proven covid infection (using PCR, serum antibody or lung TDM) and presenting at least one cutaneous lesions that occurred during the infection.",{"count":131,"type":21},"Some patients infected by covid-19 develop skin manifestations. These manifestations are still not well known and there pathophysiology remain unclear. Among them, acral manifestation resembling to chilblains appears frequent and quite specific. The aim of this project is to better characterize the cutaneous manifestations occurring during Covid-19 infection with a special focus on chilblains. These acral manifestation could be due to a direct viral effect, but also to microthrombosis or vascularitis. Understanding the pathomechanisms involved could provide interesting clue for understanding not only the skin manifestations but also some of the other systemic symptoms associated to covid-19 infection. This study plan to characterize these acral manifestations by analyzing the clinical and dermoscopic patterns and to correlate them with the non-invasive vascular explorations but also immune and coagulopathy explorations that are done in the CHU of Nice in covid-19 patients.",[245,246,247],"Skin Manifestations","COVID","Chilblains",{"date":79,"type":32},{"date":250,"type":32},"2020-04-09",{"date":83,"type":21},{"name":38,"class":39},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":40},"100354341","cutaneous-and-mucosal-manifestations-of-neurofribromatosis-type-2-in-children-under-15-100354341","NCT03893643","Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15","Multicentre Prospective Observational Study: Resentment of Mucocutaneous Manifestations and the Value of Dermatological Examination in the Early Detection of Type 2 Neurofibromatosis in Children Under 15 Years of Age","Inclusion Criteria:\n\n* age up to 15 years\n* diagnosis of neurofibromatosis type 2\n\nExclusion Criteria:\n\n* refusal to participate in the study\n* informed consent that can not be obtained because of a disability or difficulties with a - language barrier","0 Years","15 Years",{"count":263,"type":21},1000,".Neurofibromatosis type 2 is an inherently autosomal dominant genetic disease, but cases of mosaicism or de novo mutation are not uncommon. the prevalence is estimated at 1 \u002F 60,000. the clinical presentation is based on the appearance of tumors in the central and peripheral nervous system. The current average age of diagnosis is around 25 to 30 years depending on the studies. Currently, the diagnostic criteria are based on the ENT, neurological and opthalmological manifestations of the disease. Cutaneous manifestations have been described in these patients. Except now, mucocutaneous manifestations of the disease are not taken into account for depisatage or diagnosis.\n\nThe purpose of this study would be to identify the different cutaneous and mucosal manifestations in a pediatric population under 15 years of age, and to analyze whether this might be of interest in early detection of the disease in association with other symptoms.",[266,267],"Neurofibromatosis 2","Dermatology\u002FSkin - Other",{"date":79,"type":32},{"date":270,"type":32},"2019-01-01",{"date":83,"type":21},{"name":38,"class":39},{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":281,"studyType":51,"phases":4,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":289,"locationsCount":40},"100338713","nice-human-immunodeficiency-virus-hiv-cohort-100338713","NCT03690063","Nice Human Immunodeficiency Virus (HIV) Cohort","Inclusion Criteria:\n\n* Enrol consecutive patients with a scheduled visit in the outpatient clinic (regardless of CD4 cell count and ART status).\n\nExclusion Criteria:\n\n\\-",{"count":280,"type":21},2000,"3 Years","Historically, the database on the HIV was organized within the framework of the medico-economic file of the human immunodeficiency (DMI-2), introduced jointly by the Direction of Hospitals (Mission AIDS) and the INSERM at the end of the 80s. Today this database is fed via the computerized medical record NADIS. Most part of the research works on the theme of the HIV take support on this database (DAD, EuroAIDS, Neuradapt).",[284],"Human Immunodeficiency Virus",{"date":79,"type":32},{"date":287,"type":32},"1996-01-01",{"date":83,"type":21},{"name":38,"class":39},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":304,"locationsCount":40},"100338488","national-bank-alzheimer-100338488","NCT03687112","National Bank Alzheimer","BNA","Inclusion Criteria:\n\n* patients consulting in French Memory Centres\n\nExclusion Criteria:\n\n\\-","The Alzheimer's disease (MY) is a major problem of public health. The French National Database Alzheimer ( BNA) registers(records) all the medical acts made by units of memory(report) and of independent specialists in France.\n\nIn 2008, the national Plan Alzheimer 2008 - 2012 had for objective to strengthen the search(research) on the Alzheimer's disease (MY) and for related disorders(confusions), to promote an early diagnosis and to improve at the same time the management of the patients and to support careers(quarries). A specific part(party) of this plan gave rise to the creation of the French national database Alzheimer ( BNA) to supply epidemiological data as well as indicators of activity. Since 2009 The information collected(taken in) in the BNA consists of a set(group) limited by data (CIMA of information minimum Corpus Alzheimer) concerning the demographic, clinical and diagnostic data defined by national consensus. The number of variables is limited to facilitate and to improve the participation in this national database. The participants are the Centers Report (CM)((LECTURE)) and Center Memory(Report) of Resources and Search(Research) (CMRR) and independent specialists. In 2015 more than 500 Centers send CIMA to the BNA.\n\nThe plan Disease Neurodegenerative 2014 - 2019 wishes to pursue and to amplify the BNA.",[299],"Alzheimer Disease",{"date":79,"type":32},{"date":302,"type":32},"2009-01-01",{"date":83,"type":21},{"name":38,"class":39},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":182,"sex":17,"minAge":312,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":40},"100645061","exposome-pollutants-biology-in-the-older-subject-exposage-100645061","NCT07678528","Exposome, Pollutants, Biology in the Older Subject: EXPOSAGE","EXPOSAGE","Inclusion Criteria:\n\n* Aged 55 or over\n* Affiliated with or beneficiaries of a social security scheme\n* Signed the informed consent form •-Persons residing in one of the following municipalities : Antibes, Le Bar-sur-Loup, Berre-les-Alpes, Beuil, Blausasc, Breil-sur-Roya, Cabris, Cannes, Carros, Clans, Contes, Drap, L'Escarène, Escragnolles, Fontan, La Gaude, Gilette, Grasse, Lantosque, Levens, Nice, Peillon, Peymeinade, Saint-André-de-la-Roche, Saint-Etienne-de-Tinée, Sospel, Tourrettes-sur-Loup, Vence, Tende\n\nExclusion Criteria:\n\n* patients currently undergoing intensive drug treatment, including chemotherapy","55 Years",{"count":314,"type":21},400,[24],"Numerous factors, both individual and environmental, can influence aging, an individual's health, and their functional status. However, the understanding of the combined impact of lifestyle-related exposures (e.g., physical activity, diet, sleep) (personal external exposome), exposures to pollutants (environmental external exposome), and their biological responses (internal exposome)-in other words, the impact of the \"exposome\" on healthy aging-remains limited, particularly in characterizing the molecular mechanisms associated with these interactions. Exposome approaches identifying key exposures and molecular mechanisms could lead to a better understanding of how the environment, interacting with health behaviors, can affect functional status. Thus, the objective of this study is i) to evaluate the links between the external exposome, the internal exposome and the health of older and aging individuals, and ii) to identify biological markers associated with a vulnerable health status in older and aging individuals.",[318],"Aging Disorder","2026-06-24",{"date":29,"type":32},{"date":322,"type":21},"2030-09",{"date":324,"type":21},"2031-09",{"name":38,"class":39},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":40},"100465892","home-based-personalized-training-and-video-consultation-in-mitochondrial-myopathies-study-of-efficacy-and-tolerance-100465892","NCT05346627","Home Based Personalized Training and Video Consultation in Mitochondrial Myopathies: Study of Efficacy and Tolerance.","Video Consultation and Mitochondrial Myopathies: Study of Efficacy and Tolerance of a Personalized Training Program at Home","TELE-MIT","Inclusion criteria:\n\n* patient over 18 years-old,\n* with genetically-confirmed mitochondria myopathy,\n* with mitochondrial DNA mutation,\n* clinically dominant myopathic-like disorders according investigator,\n* able to walk with or without assistance,\n* likely to be followed for at least one year without interruption by video consultation (implying internet connexion with computer and camera or smartophone),\n* having given the written and informed consent and being social security member.\n* For patients in childbearing age, she must have used at least one month if reliable contraception.\n\nExclusion criteria:\n\n* patient wih pathology or comorbidity incompatible with the conduct of the study according the investigator during inclusion visit,\n* patient with physical condition incompatible with training program according investigator during inclusion visit,\n* patient having a physical tiredness and\u002For myalgia during last week with an intensity of 6 on visual and analog scale,\n* pregnant or nursing patient,\n* patient expecting pregnancy during the course of the study,\n* patient protected by law or under guardianship or curatorship, or not able to participate in a clinical trial under L.1121-16 article of French Public Health Regulations.",{"count":335,"type":21},15,[24],"Positive effect of physical activity on health arouses a strong interest at international level and is developped within the scope of national programs. Recommandations exist but must be designed for patients with functional limitations of activities.\n\nPatients with mitochondrial diseases have exercice intolerance with an increase of muscular weakness and fatigue after low exercice volume. Theses patients have functional limitations of activities. In order to establish an appropriate training programme, it will be important to define and consider the physical condition. The Society of Mitochondrial Medecine published recommandations for management of theses patients,However, theses recommandations do not allow them to propose a training program of what can be done. For these vulnerable patients, therapists are responsible fo advising a training programm without guidelines to establish its terms and conditions. In addition, some exercices do not appear to have been the subject of complete assessmeents.\n\nRegarding training programs (aerobic training, muscle reinforcement, miwed training), scientific literature shows a significant genetic and clinical variabilities, as well as a lack of data on clinical severity of included patients. In addition, the lack of informations regarding training effects of heteroplamy level limits our comprehension of mechanisms involved in adaptation of mitochondrial pool during training. Therefore, further reserchs on this subject are essential.\n\nIt is necessary to offer these patients a follow-up and personalized training program, which are in adequation with daily life. Some publications call on specifics concepts which are not compatible with day-to-day life. The investigators think it will be useful to investigate training effects in order to have practival conclusions, easily reproducible at home by patients with simple and inexpensive equipment. In this context, video consultation could allow the close follow-up of these patients.\n\nThe investigators hypothesize that a mixed training (endurance and muscle reinforcement), personalized, at home and followed by video consultation have positive effects on some physical criteria (such as musclar strength, tolerance to effort, functional abilities) without increasing heteroplasmy and creatine phosphokinase levels.",[339],"Mitochondrial Myopathies","2026-06-23",{"date":319,"type":32},{"date":343,"type":32},"2022-12-20",{"date":345,"type":21},"2027-06",{"name":38,"class":39},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":17,"minAge":355,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":40},"100633634","digestive-evolution-of-children-with-crohns-disease-or-ulcerative-colitis-whose-anti-tnf-treatment-was-switched-to-ustekinumab-due-to-paradoxical-psoriasis-100633634","NCT07529236","Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,","Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Was Switched to Ustekinumab Due to Paradoxical Psoriasis: Real Life Data","INFLISWITCH","Inclusion Criteria:\n\n1. Patients capable of giving their non-opposition\n2. Patient \\\u003C19 years\n3. Diagnosis of IBD established\n4. Having received an anti-TNFα for IBD for at least 3 months\n5. Having stopped the anti-TNFα for a severe paradoxical psoriasis resistant to usual treatments (topical or systemic) diagnosed by a dermatologist\n6. Having received Ustekinumab in relay of the anti-TNFα\n\nExclusion Criteria:\n\n1. Patient \\> 18 years\n2. Diagnosis of IBD not confirmed\n3. Discontinuation of anti-TNFα for a cause other than psoriasis","6 Years","17 Years",{"count":358,"type":21},40,[24],"Inflammatory bowel diseases (IBD) include Crohn's disease (CD) and ulcerative colitis (UC). They cause abdominal pain and chronic diarrhea and\u002For rectal bleeding, which can lead to weight loss and malnutrition. IBD affects people of all ages but usually appears before the age of 30, most often between the ages of 14 and 24. Childhood IBD is generally considered to be more progressive than adult IBD. Although there is no cure for IBD, many medications can help reduce inflammation and relieve IBD symptoms. Anti-TNF drugs (infliximab and adalimumab) are used early in high-risk patients or when standard treatments have failed. Cutaneous side effects are common in pediatrics (\\>10%), primarily psoriasiform eruptions (41%), often exudative, affecting skin folds and scalp, recurrent skin infections (20%), and eczematous eruptions (10%). Only 5% of patients need to discontinue treatment due to these side effects. In such cases, the recommended treatment is ustekinumab (European guidelines). While this treatment has been described as effective in patients who have failed anti-TNFα therapy, little data is available on the gastrointestinal and dermatological outcomes of patients on anti-TNFα therapy who switch to ustekinumab for dermatological reasons.",[362],"Chronic Inflammatory Bowel Diseases","2026-06-22",{"date":77,"type":32},{"date":366,"type":32},"2026-04-20",{"date":368,"type":21},"2027-10-01",{"name":38,"class":39},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":22,"phases":379,"briefSummary":380,"conditions":381,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":40},"100638867","comparison-of-two-general-anesthesia-maintenance-strategies-on-intraoperative-visibility-during-arthroscopic-rotator-cuff-surgery-a-randomized-trial-100638867","NCT07628244","Comparison of Two General Anesthesia Maintenance Strategies on Intraoperative Visibility During Arthroscopic Rotator Cuff Surgery: A Randomized Trial","CLEAR-SHOULDER","Inclusion Criteria:\n\n1. Patient aged 18 or over\n2. Patient scheduled for elective rotator cuff repair arthroscopy (RCRA), performed in the \"beach-chair\" position under general anesthesia combined with an interscalene block (with or without standard associated procedures such as acromioplasty and\u002For tenotomy\u002Ftenodesis of the long biceps). Procedures for instability (Bankart\u002FLatarjet), fractures, capsulitis, simple lavage, or any arthroscopy not focused on rotator cuff repair (RCR) are not eligible.\n3. Patient with an ASA score of I to IV\n4. Patient affiliated to a social security scheme,\n5. Patient having given written consent following written and oral information.\n\nExclusion Criteria:\n\n1. Patients with a contraindication to any of the study agents, including known hypersensitivity or allergy to any of these agents or to any of their excipients.\n2. Patients with known coagulopathy (abnormal PT\u002FINR; platelets \\\u003C 100,000\u002FL) or\n3. Patients with active preoperative hemarthrosis or local infection.\n4. Non-elective (emergency) surgery or a procedure whose initial objective is not rotator cuff repair arthroscopy (RCRA). Note: Intraoperative conversion to open surgery is not an exclusion criterion; it will be considered an intraoperative event and managed in the analysis according to the intention-to-treat (ITT) principle, with a sensitivity analysis procedure described in the statistical plan.\n5. Uncooperative patient, inability to consent\n6. Pregnant women\n7. Patient protected by law under guardianship or curatorship, or unable to participate in a clinical study under article L. 1121-16 of the French Public Health Code.",{"count":378,"type":21},110,[24],"Shoulder arthroscopy is one of the most common orthopedic procedures, and the quality of the surgeon's view inside the joint is critical to its safety and success. Unlike limb surgery, no tourniquet can be applied to the shoulder, so surgical visibility depends almost entirely on how much bleeding occurs within the joint - which is itself influenced by the anesthetic drugs used to keep the patient asleep.\n\nTwo standard techniques exist for maintaining general anesthesia: inhaled anesthesia (sevoflurane) and total intravenous anesthesia (TIVA, using propofol). Evidence from other types of keyhole surgery (nasal, ear) suggests that propofol may produce better surgical visibility, possibly because sevoflurane causes slightly greater dilation of the smallest blood vessels in tissue, leading to more bleeding into the joint. However, in shoulder arthroscopy specifically, the data are scarce and contradictory.\n\nCLEAR-SHOULDER is a randomized, single-blind trial designed to determine whether propofol-based intravenous anesthesia provides superior intraoperative visibility compared to sevoflurane-based inhaled anesthesia during arthroscopic rotator cuff repair. Surgical visibility will be assessed from blinded video recordings of each procedure using the validated modified Fromme-Boezaart score. An exploratory artificial intelligence analysis of the arthroscopic videos will also be conducted.\n\nSecondary outcomes include operating time, irrigation fluid consumption, hemodynamic stability, vasopressor requirements, surgeon satisfaction, postoperative recovery, and environmental impact of each anesthetic strategy.",[382,383,384],"Rotator Cuff Injuries","Anesthesia, General","Arthroscopy","2026-06-19",{"date":319,"type":32},{"date":388,"type":32},"2026-06-18",{"date":390,"type":21},"2028-03-18",{"name":38,"class":39},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":22,"phases":400,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":40},"100622804","superficial-vein-thrombosis-of-the-upper-limb-in-bacteremia-associated-with-piccline-and-midline-catheters-frequency-and-clinical-consequences-100622804","NCT07388381","Superficial Vein Thrombosis of the Upper Limb in Bacteremia Associated With PICCline and Midline Catheters: Frequency and Clinical Consequences","THROMBI-CATH","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Hospitalization in a department of Nice University Hospital\n* Expected length of hospitalization ≥ 72 hours\n* Diagnosis of catheter-related bacteremia on PICCline or Midline.\n* Affiliation with a social security system\n* No objection to the study\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Legal protection measures (patients under guardianship, trusteeship, or judicial protection)\n* Inability to remove the catheter\n* Doppler ultrasound showing DVT in the upper limb at selection.\n* Inability to perform the initial routine Doppler ultrasound\n* Withdrawal of the patient's consent",{"count":50,"type":21},[24],"The use of long-term peripheral venous catheters inserted in the upper limb (PICC lines and Midlines) has increased markedly over recent years.\n\nCatheter-related bacteremias and venous thromboses are the main complications associated with these catheters. These events may occur independently or simultaneously. In addition, venous thromboses may involve the superficial venous system (SVT) or the deep venous system (DVT).\n\nCurrent guidelines define septic thrombophlebitis as the association of a bacteremia and a DVT along the venous course of the catheter. This represents a severe complication of catheter-related bacteremia, leading to a modification in the duration of antibiotic therapy. However, SVTs associated with catheter-related bacteremias along the catheter pathway are not included in the definition of septic thrombophlebitis and are not addressed by specific recommendations.\n\nThe objective of this study is therefore to assess the impact of upper-limb SVT on the frequency of unfavorable outcomes in catheter-related bacteremias related to PICC and Midline catheters, in order to determine whether superficial venous thrombosis occurring in the context of a catheter-related bacteremia should be considered a distinct entity not falling under the diagnosis of septic thrombophlebitis (and therefore not requiring a modification of antibiotic treatment duration, in accordance with current guidelines), or whether, conversely, it should be considered equivalent to septic thrombophlebitis, as is the case for deep venous thrombosis.",[403],"Catheter Associated Infection",{"date":363,"type":32},{"date":406,"type":32},"2026-02-09",{"date":408,"type":21},"2027-10-30",{"name":38,"class":39},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":17,"minAge":418,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":40},"100622805","polypharmacy-on-healthy-aging-in-people-living-with-hiv-over-the-age-of-75-100622805","NCT07388394","Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75","Describe and Evaluate the Impact of Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75 Who Are Being Treated at Nice University Hospital.","POLYVIH","Inclusion Criteria:\n\n* HIV-positive\n* Aged 75 or over\n* Affiliated with the social security system\n* Having expressed no objection to participating in the study\n\nExclusion Criteria:\n\n* Refusal to participate\n* Known severe cognitive impairment preventing the interview from being conducted\n* Patient under guardianship or conservatorship","75 Years",{"count":420,"type":21},136,[24],"Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. This population is exposed to high multimorbidity, leading to frequent polypharmacy, defined as the regular use of at least five medications. Polypharmacy also has a qualitative dimension, including potentially inappropriate prescriptions. It increases the risk of adverse effects and drug interactions and impairs quality of life. A coordinated geriatric approach is therefore essential to optimize care. Healthy aging, promoted by the WHO, aims to improve the lives of older people. In this context, a study will be conducted at the Nice University Hospital among PLHIV aged 75 and over. It will collect quantitative data, the results of which will enable us to consider, if necessary, adapting the care pathways of these patients whose needs are complex.",[424],"Virus-HIV",{"date":363,"type":32},{"date":427,"type":32},"2026-01-28",{"date":429,"type":21},"2027-05-31",{"name":38,"class":39},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":441,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":40},"100600399","phase-2-impact-of-dapagliflozin-for-the-regulation-of-immunological-activity-in-membranous-nephropathy-100600399","NCT07096986","Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy","Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous","FORXIGEM","Inclusion Criteria:\n\n* Participants ≥ 18 years old and \\\u003C 85 years old;\n* Membranous Nephropathy associated with anti-PLA2R1 autoantibodies;\n* Urine Protein Creatinine Ratio (UPCR) between 0.5 g\u002Fg and 3.5 g\u002Fg;\n* Immunological relapse defined by an increase in anti-PLA2R1 antibody concentration \\> 14 RU\u002FmL after a phase of anti-PLA2R1 antibody negativation, (i.e. immunological remission) and complete or partial clinical remission;\n* Antiproteinuric treatment at maximal and stable dose. According to KDIGO 2024 guidelines on management of glomerular diseases and the French recommendations (PNDS GEM 2022), symptomatic treatment of membranous nephropathy should include: (i) a low sodium diet, (ii) a diuretic and (iii) an angiotensin-converting enzyme inhibitor or an angiotensin 2 receptor blocker at maximal tolerated dose (i.e., absence of orthostatic hypotension and no increase in serum creatinine \\>30%).\n\nExclusion Criteria:\n\n* Immunosuppressive treatment for MN in the 6 months prior to the selection visit;\n* Secondary MN (associated with cancer, infectious disease, autoimmune or iatrogenic disease);\n* Active nephrotic syndrome defined according to KDIGO guidelines as proteinuria \\> 3.5 g\u002Fday (or 3.5 g\u002Fg in a urine sample) and albumin \\\u003C 30 g\u002FL;\n* No previous history of immunological remission (anti-PLA2R1 antibodies \\\u003C 14 RU\u002FmL in ELISA or negative indirect immunofluorescence) or clinical remission (partial or complete);\n* Galactose intolerance, total lactase deficiency or glucose-galactose malabsorption disorders\n* Patients at risk for ketoacidosis including patients with a low reserve of functional beta cells (e.g. patients with type 2 diabetes with low C-peptide or latent autoimmune diabetes mellitus or patients with a history of pancreatitis or patients who are receiving insulin treatment), patients with conditions leading to reduced food intake or severe dehydration, patients with low insulin reserve, and patients with increased insulin requirements due to acute medical illness, surgery or excessive alcohol consumption;\n* Type 1 diabetes;\n* Pregnancy or breastfeeding;\n* Estimated CKD-EPI Glomerular Filtration Rate (eGFR) \\\u003C 25 ml\u002Fmin\u002F1.73m2;\n* Severe liver failure (Child-Pugh stage C);\n* NYHA functional class IV heart failure;\n* Patients already currently receiving dapagliflozin or another SGLT2 inhibitor for another condition;\n* Repeated urinary tract infections;\n* Hypersensitivity to the active substance or excipients.","84 Years",{"count":96,"type":21},[442],"PHASE2","WHY IS THIS RESEARCH BEING CONDUCTED? Membranous glomerulonephritis (MN) is an autoimmune disease that affects the kidneys through autoantibodies, meaning that antibodies produced by your body attack your own kidney cells. The appearance of these autoantibodies can be explained in part by a disruption in the immune response. Patients with this disease are treated with immunosuppressive drugs such as rituximab. The aim of this treatment is to reduce the production of all antibodies, including those responsible for the disease. Despite this treatment, some patients may experience a relapse of the disease. These relapses can be complicated by infections, blood clots in the blood vessels, and, in the long term, can lead to kidney failure and an increased cardiovascular risk. Relapses can also have an impact on patients' social and professional lives.\n\nDapagliflozin is a diuretic medication, which means that it is used to increase urine production and eliminate excess salt and water from the body to reduce edema (swelling). It is currently prescribed and authorized for patients with type 2 diabetes, heart failure and chronic kidney disease. This treatment has been shown to reduce the amount of proteins in the urine and protect the kidneys and cardiovascular system in patients with chronic kidney disease. A study has also shown that dapagliflozin may have an effect on the immune response.\n\nWHAT DOES IT INVOLVE? The aim of our study will be to evaluate the efficacy of dapagliflozin in reducing disease autoantibodies and preventing relapses.\n\nThis research will be conducted at the Nice University Hospital and the Nîmes University Hospital. We expect to 20 patients to be recruited with an anti-PLA2R1 positive MN.\n\nParticipation in the study will last 6 months. The research is funded by Nice University Hospital. WHAT IS THE TREATMENT BEING STUDIED? It is dapagliflozin, a drug that is increasingly used routinely in patients with nephrotic syndrome (including MN) for its ability to reduce protein in the urine. Its effect on the immune system in MN has not yet been studied",[445],"Glomerulonephritis",{"date":363,"type":32},{"date":448,"type":21},"2026-11-01",{"date":450,"type":21},"2027-11",{"name":38,"class":39},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":22,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":472},"100597432","impact-of-three-probabilistic-antibiotic-therapy-on-digestive-microbiota-and-colonization-with-multi-resistant-bacteria-100597432","NCT07058415","Impact of Three Probabilistic Antibiotic Therapy on Digestive Microbiota and Colonization With Multi-resistant Bacteria","Osteoarticular Infections on Equipment: Impact of Three Probabilistic Antibiotic Therapy on Digestive Microbiota and Colonization With Multi-resistant Bacteria","HOPE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Indication for prosthetic revision (PTG, PUC, PTH or hip hemiarthroplasty, PTE) or internal osteosynthesis with suspicion of IOAM following the opinion of a Réunion de concertation Pluridisciplinaire (RCP) on complex osteoarticular infections\n* Normal CPK level according to laboratory standard\n* Social security affiliation\n* Signature of informed consent\n* Negative pregnancy test for women of childbearing age.\n\nExclusion Criteria:\n\n* Antibiotic therapy in the 3 months prior to inclusion\n* Clinical or radiological signs making HAI highly probable: scar discharge and\u002For peri-scar cellulitis fistula or abscess, bacteremia\n* positive bacterial culture from joint puncture or biopsy prior to revision\n* Chronic inflammatory bowel disease.\n* Previous surgical resection of small intestine or colon.\n* Hypersensitivity to daptomycin or any of its excipients.\n* Hypersensitivity to cefepime or any of its excipients or to other beta-lactamins.\n* Hypersensitivity to piperacillin+tazobactam or to any of the excipients or to other beta-lactamines.\n* Hypersensitivity to ceftobiprole or to any of the excipients or to other beta-lactamines.\n* Renal insufficiency with GFR \\\u003C 50ml\u002Fmin\u002F1.73 m2 (CKD-EPI).\n* Treatment with bosentan.\n* Treatment with probenecid.\n* Pre-existing seizure disorder.\n* Contraindication to L-arginine, acidosis, hyperkalemia that cannot be corrected.\n* Treatment with HMG-CoA reductase inhibitors.\n* Treatment with statins (pitavastin, pravastatin, rosuvastatin) or glyburide.\n* Patients in a medical emergency.\n* Pregnant or breast-feeding women.\n* Patient participating in another ongoing trial.\n* Mental state rendering the patient incapable of understanding this research.\n* Patient deprived of liberty by administrative or judicial decision.",{"count":461,"type":21},75,[24],"In the event of suspected osteoarticular material infection (OAMI), broad-spectrum probabilistic antibiotic therapy is recommended immediately after revision surgery. There are no efficacy data to suggest that any particular to favour any particular molecule. However, the choice may depend on the impact on the microbiota and on Enterobacteriaceae colonization with multi-resistant Enterobacteriaceae. Our aim is to evaluate three different strategies efepime+daptomycin C+D, piperacillin-tazobactam+daptomycin (PT+D) and ceftobiprole (CFB).",[465],"Osteoarticular Material Infection",{"date":363,"type":32},{"date":468,"type":21},"2026-07",{"date":470,"type":21},"2027-05",{"name":38,"class":39},4,{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":40},"100592400","immunological-impact-of-a-post-cell-therapy-treatment-with-flt3-inhibitors-100592400","NCT06992934","Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors","Non Interventional Study Aiming to Assess the Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors on the Phenotype, the Metabolism, the Function of T-cells and Monocytes and Macrophages","TARGETALLO","Inclusion Criteria:\n\n* Patient \\> 18y\u002Fo\n* Patient who received an allogeneic stem cell transplantation for an acute myeloid leukemia and who will receive gilteritinib as post transplantation maintenance\n* Matched related, matched unrelated, mismatched unrelated and haploidentical donors\n\nExclusion Criteria:\n\n* Minors\n* Pregnant women\n* Patient under 'tutelle', 'curatelle' or in prison\n* Patient who has been treated for a solid tumor in the past 2 years\n* Known human immunodeficiency virus (HIV) infection or HIV-related malignancy\n* Clinically active hepatitis B or hepatitis C infection\n* Known allergy or hypersensitivity to gilteritinib",{"count":20,"type":21},[24],"Allogeneic hematopoietic stem cell transplantation (aHSCT) is the only curative option for many hematological maligancies. The main cause of death following HSCT is the relapse of the original disease.\n\nFew strategies have been developed to prevent relapse after bone marrow transplantation. New prophylactic strategies are needed to decrease the relapse incidence without increasing the non-relapse mortality in the post-transplant area. Several drugs are currently being explored as maintenance in several AML subgroups such as FLT3 ITD\u002Fmutated AML.\n\nA specific group of AML patients display the FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) or mutation. These recurrent genetic abnormalities account for 30-35% of all AML patients. Because FLT3 is a tyrosine kinase, it can be targeted using tyrosine kinase inhibitors (TKI). Originally limited to first generation sorafenib and Midostaurin, the FLT3 TKI now include second generation Gilteritinib, crenolanib and quizartinib13. Because many FLT3 AML patients would relapse after aHSCT, the use of sorafenib, the only FLT3 TKI available at that time, in a post-transplant setting started to be evaluated.\n\nSorafenib is a multi-kinase inhibitor that not only inhibit FLT3 but also the RAS, RAF, KIT, and the VEGF and platelet-derived growth factor receptor. Several retrospective trials reported the safety and efficiency of a sorafenib maintenance.\n\nIn recent years, a mounting piece of evidence suggests that sorafenib may have an impact on several immune cells as T cell populations, dendritic cells, macrophages and myeloid-derived immunosuppressor cells (MDSC). Other more potent and more specific FLT3 inhibitors are currently under investigation both in combination with chemotherapy before transplantation and as post transplantation maintenance. In this line, crenolanib and Gilteritinib are two potent and more specific TKI that proved more effective than sorafenib in the treatment of FLT3 ITD\u002FTKD relapsed, refractory AML patients. These drugs demonstrated a higher response rate in R\u002FR patients. These two drugs are part of the future standard of care in FLT3 AML but their immunological impact has never been studied.\n\nAt a time where cellular therapies (allogeneic stem cell transplantation but also CAR T cells) and targeted therapies are becoming the central point of cancer treatment, it appears mandatory to better understand the interactions between the two. The goal of our research project which covers fundamental and clinical aspects of AML post-transplant treatments is devoted to a better understanding of the impact of Gilteritinib on the immune cells in order to rationalize their use after aHSCT. A better characterization of the action of these drugs on the immune system is urgently needed to develop new prophylactic strategies which could decrease the relapse incidence without increasing the non-relapse mortality in the post-transplant area. This program is proposed for a period of 3 years, time necessary to perform all the in vitro and ex vivo approaches and to recruit a sufficient number of patients eligible for aHSCT.",[485],"Hematological Malignancies",{"date":363,"type":32},{"date":488,"type":21},"2026-09",{"date":490,"type":21},"2028-08",{"name":38,"class":39},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":182,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":22,"phases":502,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":40},"100556674","covid-19-long-immunit-imagerie-cliim-100556674","NCT06528171","Covid-19 Long Immunité IMagerie (CLIIM)","Specific Markers of Covid-long Syndrome: Identifying the Mechanisms Involved With a View to Defining Diagnostic Criteria","CLIIM","FOR CL+ PATIENTS\n\nInclusion Criteria:\n\n* Case definition in line with WHO Delphi process\n\nExclusion Criteria:\n\n* History of chronic fatigue syndrome diagnosed before or after Covid.\n* History of progressive psychiatric pathology.\n* History of acute Covid requiring admission to intensive care and mechanical ventilation.\n* No social security affiliation.\n\nFOR CONTROL (CL-)\n\nInclusion Criteria:\n\n* History of acute COVID-19, mild, moderate or severe (episode at least 3 months at the time of inclusion).\n* Absence of persistent symptoms more than 3 months after first Covid symptoms (or mild not affecting daily activities).\n\nExclusion Criteria:\n\n* History of progressive psychiatric pathology.\n* History of acute Covid requiring admission to intensive care and mechanical ventilation.\n* No social security affiliation.\n* Pregnant or breast-feeding.",{"count":501,"type":21},200,[24],"Covid-long pathology affects a large number of patients, and represents a major medical, economic and societal challenge. To date, we have no objective criterion for a definitive diagnosis, nor any predictive tool for monitoring the evolution of Covid-long. Based on recruitment from the infectious diseases department of Nice University Hospital, the investigator's team wants to conduct an innovative pathophysiological study to better define the disease and identify specific biomarkers that could subsequently be used as a diagnostic tool for Covid-long. 120 participants will be initially included for the model learning phase: 60 controls in the CL- cohort and 60 patients in the CL+ cohort. Then 80 patients (40 CL+ and 40 Cl-) will be enrolled for the model validation phase.",[505],"COVID Long-Haul",{"date":363,"type":32},{"date":508,"type":32},"2024-12-06",{"date":510,"type":21},"2028-06",{"name":38,"class":39},""]